A new trading day began on Monday, with Apellis Pharmaceuticals Inc (NASDAQ: APLS) stock price up 1.27% from the previous day of trading, before settling in for the closing price of $17.30. APLS’s price has ranged from $16.65 to $43.99 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 92.54%. Meanwhile, its annual earnings per share averaged -7.88%. With a float of $104.61 million, this company’s outstanding shares have now reached $125.66 million.
Considering the fact that the conglomerate employs 710 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 84.82%, operating margin of -21.11%, and the pretax margin is -25.18%.
Apellis Pharmaceuticals Inc (APLS) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Apellis Pharmaceuticals Inc is 16.77%, while institutional ownership is 99.31%. The most recent insider transaction that took place on May 12 ’25, was worth 3,924,267. Before that another transaction happened on Mar 17 ’25, when Company’s VP/Chief Accounting Officer sold 183 for $24.82, making the entire transaction worth $4,543. This insider now owns 47,955 shares in total.
Apellis Pharmaceuticals Inc (APLS) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -7.88% per share during the next fiscal year.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Trading Performance Indicators
Here are Apellis Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.62. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.84.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.79, a number that is poised to hit -0.43 in the next quarter and is forecasted to reach -0.49 in one year’s time.
Technical Analysis of Apellis Pharmaceuticals Inc (APLS)
Compared to the last year’s volume of 2.2 million, its volume of 4.24 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 21.79%. Additionally, its Average True Range was 1.19.
During the past 100 days, Apellis Pharmaceuticals Inc’s (APLS) raw stochastic average was set at 4.57%, which indicates a significant decrease from 21.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.39% in the past 14 days, which was lower than the 54.98% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $21.36, while its 200-day Moving Average is $29.32. Nevertheless, the first resistance level for the watch stands at $17.96 in the near term. At $18.41, the stock is likely to face the second major resistance level. The third major resistance level sits at $18.75. If the price goes on to break the first support level at $17.17, it is likely to go to the next support level at $16.83. Now, if the price goes above the second support level, the third support stands at $16.38.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) Key Stats
With a market capitalization of 2.20 billion, the company has a total of 125,682K Shares Outstanding. Currently, annual sales are 781,370 K while annual income is -197,880 K. The company’s previous quarter sales were 212,530 K while its latest quarter income was -36,350 K.
